Physician profile
Scott Williams
NPI 1508862343
$12,594.19
in general payments reported to CMS, 2019-2025
53 companies · $2,035 in 2025
The $2,035 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,855 · 2020: $1,006 · 2021: $1,971 · 2022: $2,039 · 2023: $1,905 · 2024: $1,782 · 2025: $2,035.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,720 · Education: $2.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,719.70 |
| Education | $2.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $2,844.42 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $1,096.33 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $767.14 | 2019-2025 | Jardiance, Ofev, Tradjenta |
| Lilly USA, LLC | $766.10 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $671.99 | 2019-2025 | Vraylar, Ubrelvy |
| Pfizer INC. | $606.33 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $578.58 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $540.09 | 2019-2023 | Xarelto |
| Merck Sharp & Dohme LLC | $475.68 | 2019-2024 | Verquvo, Dificid, Gardasil 9 |
| Amarin Pharma, INC. | $417.40 | 2019-2022 | |
| Indivior INC. | $368.63 | 2024-2025 | Sublocade |
| Takeda Pharmaceuticals U.S.A., INC. | $306.79 | 2019-2025 | Trintellix |
| Glaxosmithkline, LLC. | $241.36 | 2020-2025 | Trelegy Ellipta |
| Exact Sciences Corporation | $241.07 | 2023-2025 | Cologuard Collection Kit |
| Astellas Pharma US INC | $224.34 | 2021-2025 | Veozah |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.